DMPA: Time to repeal black box warning?

October 2011
Contraceptive Technology Update;Oct2011, Vol. 32 Issue 10, p112
Academic Journal
A recently published editorial is calling for the repeal of the black box warning to the labeling for the contraceptive injection, depot medroxyprogesterone acetate (DMPA). The Food and Drug Administration added the warning in 2004 advising that prolonged use might result in bone mineral density loss. The guidance contained in the DMPA black box is not based on evidence, and the warning deprives women of long-term use of a safe and effective contraceptive, the editorial states. The warning cautions users that DMPA should be used as a long-term birth control method (longer than two years) only if other birth control methods are inadequate.


Related Articles

  • FDA advisers uneasy about long-term bisphosphonate use. Traynor, Kate // American Journal of Health-System Pharmacy;11/1/2011, Vol. 68 Issue 21, p2006 

    The article reports that FDA's panel of experts advised against the long-term use of bisphosphonates for osteoporosis, and suggested that biophosphonate therapy be reevaluated on a periodic basis. It mentions the National Osteoporosis Foundation recommendation on biophosphonate use, and includes...

  • FDA: Possible increased risk of thigh bone fracture with bisphosphonates Labeling change adds warning about possible risks of long-term use of osteoporosis drugs.  // Biomedical Market Newsletter;12/20/2010, p52 

    The article reports that the U.S. Food & Drug Administration (FDA) has warned patients and health care providers about the possible risk of atypical thigh bone (femoral) fracture in patients who take bisphosphonates. It is a class of drugs which is used to prevent and treat osteoporosis....

  • Possible Fracture Risk With Osteoporosis Drugs.  // Biomedical Market Newsletter;12/20/2010, p56 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take drugs known as bisphosphonates to treat osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these prescription...

  • FDA Drug Safety Communication: Safety update for osteoporosis drugs, bisphosphonates, and atypical fractures.  // Biomedical Market Newsletter;12/20/2010, p57 

    The article reports that the Food & Drug Administration (FDA) is warning about a possible risk of a rare type of thigh bone fracture in people who take bisphosphonates, a kind of drugs used for treating osteoporosis. FDA saw increasing cases of femoral fracture in patients taking these...

  • Osteoporosis After Long-Term Depot Medroxyprogesterone: We Need More Data on Fracture Risk. Downs, Robert W.; Yazbeck, Cynthia F. // Journal of Women's Health (15409996);Aug2015, Vol. 24 Issue 8, p619 

    The author reflects on the study "Prevalence of low bone mass and osteoporosis in long-term users of the injectable contraceptive depot medroxyprogesterone acetate" by W. Modesto and others. Topics discussed include low risk of fracture in individuals treated with injectable depot...

  • Bone risk low with OTC GERD drugs.  // Clinical Advisor;May2011, Vol. 14 Issue 5, p23 

    The article offers information on the conclusion by the U.S. Food and Drug Administration (FDA) that fracture is unlikely with the short-use use of low-dose proton pump inhibitors (PPI).

  • LEGAL & REGULATORY: Herbal Experts Say CSPI Petition for St. John's Wort Warning Inaccurate. Stafford, Lindsay // HerbalGram;Feb-Apr2012, Issue 93, p58 

    The article reports on a November 2011 decision which the Center for Science in the Public Interest made to urge the U.S. Food and Drug Administration to require detailed warning labels on all St. John's wort products, which are used to treat depression, sleep disorders, anxiety and other...

  • Should teens be given depot medroxyprogesterone acetate? Edelman, Alison; Jensen, Jeffrey T. // Contemporary OB/GYN;Apr2006, Vol. 51 Issue 4, p54 

    Examines the prescription of depot medroxyprogesterone acetate (DMPA) as birth control method to teenagers following the black box warning of the U.S. Food and Drug Administration on its adverse effects on bone density. Prevention of the pituitary gland to secrete gonadotropin by the DMPA;...

  • Should adolescent girls be given depot medroxyprogesterone acetate? Edelman, Allison; Jensen, Jeffrey T. // Contemporary Pediatrics;Sep2006, Vol. 23 Issue 9, p105 

    The article examines the health risks if adolescent girls are to be given depot medroxyprogesterone acetate as an effective birth control method in light of a black box warning from the U.S. Food and Drug Administration. The drug includes a progestin-only formulation that can be safely used by...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics